Detalhe da pesquisa
1.
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
PLoS Med
; 13(10): e1002139, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27727279
2.
Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE).
Arthritis Res Ther
; 24(1): 81, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35365179
3.
Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D).
Trials
; 16: 86, 2015 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25881192